Africa Finance Today
SEE OTHER BRANDS

The best finance and banking news from Africa

Africa Finance Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa Finance Today.

Press releases published on May 7, 2025

Verisk Reports First-Quarter 2025 Financial Results

Verisk Reports First-Quarter 2025 Financial Results

First quarter revenue of $753 million, up 7.0%, and up 7.9% on an organic constant currency (OCC) basis. Net income of $232 million, up 5.9%. Adjusted EBITDA, a non-GAAP measure, of $417 million, up 9.5%, and up 9.5% on an OCC basis. Diluted GAAP earnings …

Vertex Announces First Quarter 2025 Financial Results

Vertex Announces First Quarter 2025 Financial Results

KING OF PRUSSIA, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its first quarter ended March 31, 2025. “Vertex …

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …

Avista Corp. Reports Financial Results for the First Quarter of 2025, Confirms 2025 Earnings Guidance

Avista Corp. Reports Financial Results for the First Quarter of 2025, Confirms 2025 Earnings Guidance

SPOKANE, Wash., May 07, 2025 (GLOBE NEWSWIRE) -- Avista Corp. (NYSE: AVA) today announced financial results for the first quarter of 2025. Net income and earnings per diluted share for the first quarter of 2025 compared to the first quarter of 2024 are …

TransAlta Reports First Quarter 2025 Results and Reaffirms Annual Guidance

TransAlta Reports First Quarter 2025 Results and Reaffirms Annual Guidance

CALGARY, Alberta, May 07, 2025 (GLOBE NEWSWIRE) -- TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) today reported its financial results for the first quarter ended March 31, 2025. "Our business delivered strong operational …

Hain Celestial Reports Fiscal Third Quarter 2025  Financial Results

Hain Celestial Reports Fiscal Third Quarter 2025 Financial Results

HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- The Hain Celestial Group, Inc. (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its …

Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive

Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive

•  Non-Dilutive Financing •  Up to US$10 Million Promissory Note Provided by Vantive •  If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization •  Company to host Corporate Update Call on May 15, 2025 TORONTO, May 07, …

Sprott Announces First Quarter 2025 Results

Sprott Announces First Quarter 2025 Results

TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the quarter ended March 31, 2025. Management commentary "Sprott’s Assets Under Management (“AUM”) ended the first …

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) …

Immunocore reports first quarter financial results and provides a business update

Immunocore reports first quarter financial results and provides a business update

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On …

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues …

Climb Channel Solutions Partners with Smartsheet for Industry-Leading Collaborative Work Management

Climb Channel Solutions Partners with Smartsheet for Industry-Leading Collaborative Work Management

EATONTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) is excited to be adding Smartsheet, the AI-enhanced …

Dayforce Reports First Quarter 2025 Results¹

Dayforce Reports First Quarter 2025 Results¹

Dayforce® recurring revenue, excluding float, of $323 million, up 14%, or 16% on a constant currency basis Total revenue of $482 million, up 12%, and excluding float, up 15%, or 17% on a constant currency basis Net cash provided by operating activities of …

Chicago Atlantic Real Estate Finance Announces First Quarter 2025 Financial Results

Chicago Atlantic Real Estate Finance Announces First Quarter 2025 Financial Results

CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its results for the first quarter ended March 31, …

Amarin Reports First Quarter 2025 Financial Results

Amarin Reports First Quarter 2025 Financial Results

-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing …

KVH Industries Reports First Quarter 2025 Results

KVH Industries Reports First Quarter 2025 Results

MIDDLETOWN, R.I., May 07, 2025 (GLOBE NEWSWIRE) -- KVH Industries, Inc. (Nasdaq: KVHI), reported financial results for the quarter ended March 31, 2025 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can …

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease …

 Bitfarms Schedules First Quarter 2025 Conference Call on May 14, 2025

Bitfarms Schedules First Quarter 2025 Conference Call on May 14, 2025

TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a global energy and compute infrastructure company, will report its first quarter 2025 financial results on Wednesday, May 14th before the market opens. Management will host a …

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase …

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service